Pharma: Page 8
-
Sundry Photography via Getty Images
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market
A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.
By Michael Gibney • Dec. 19, 2024 -
Scott Olson via Getty Images
Big Pharma’s new DTC play: partnering with digital health providers
The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.
By Amy Baxter • Dec. 18, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PeopleImages via Getty Images
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Stock via Getty Images
A biotech’s race to tackle the most severe hepatitis
Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.
By Alexandra Pecci • Dec. 17, 2024 -
Courtesy of Roche
3 closely watched drugs that failed in the clinic
How recent setbacks and scattered successes could impact various sectors of the industry.
By Kelly Bilodeau • Dec. 16, 2024 -
Stock via Getty Images
Oncology, obesity and more: Where pharma R&D is headed in 2025
With a little more certainty coming to the market, the R&D environment in 2025 will be about pipeline prioritization and accelerating M&A.
By Amy Baxter • Dec. 16, 2024 -
Stock via Getty Images
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
By Meagan Parrish • Dec. 13, 2024 -
Permission granted by Regeneron
Q&ARegeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.
By Michael Gibney • Dec. 12, 2024 -
Courtesy of Eli Lilly
GLP-1 compounding is still in limbo. Will the FDA leave it for the next administration?
The agency has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now.
By Amy Baxter • Dec. 11, 2024 -
Pony Wang via Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 11, 2024 -
Justin Sullivan via Getty Images
What’s next for 23andMe?
Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.
By Alexandra Pecci • Dec. 10, 2024 -
Magdalena Wygralak via Getty Images
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide.
By Michael Gibney • Dec. 10, 2024 -
Stock via Getty Images
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.
By Amy Baxter • Dec. 9, 2024 -
Stock via Getty Images
Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready?
The push to bring generic drug production back home has failed to reach a critical mass.
By Meagan Parrish • Dec. 6, 2024 -
Permission granted by Astellas
Q&AHow Astellas juggles the moving parts of cancer precision medicine development
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
By Michael Gibney • Dec. 5, 2024 -
Courtesy of GSK
GSK taps a startup for shot at Alzheimer’s drug
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By Jacob Bell • Dec. 5, 2024 -
Noam Galai via Getty Images
With Makary set to face FDA commissioner hearings, how deep do his industry ties run?
Dr. Marty Makary’s conflicts of interest could come into question before he is confirmed as the next FDA commissioner.
By Amy Baxter • Dec. 4, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Getty Images via Getty Images
Specialized CROs aim to boost participation among women and other underrepresented groups
Lindus Health’s women-focused CRO is the latest in a handful of research efforts to target specialized — and underrepresented — populations.
By Alexandra Pecci • Nov. 27, 2024 -
Kevin Dietsch / Staff via Getty Images
How the incoming administration could impact FTC’s approach to pharma M&A
Pharma companies looking to get a break from the FTC under a new administration may be out of luck.
By Kelly Bilodeau • Nov. 26, 2024 -
Win McNamee via Getty Images
Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?
Both Trump appointees have promised to bring sweeping changes to several healthcare agencies.
By Amy Baxter • Nov. 25, 2024 -
Justin Sullivan via Getty Images
Will Walgreens’ store closures derail its clinical trial aims?
Despite a plan to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy juggernaut remains committed to drug research.
By Meagan Parrish • Nov. 22, 2024 -
George Clerk via Getty Images
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
By Kristin Jensen • Nov. 21, 2024 -
Permission granted by Merck & Co.
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
By Michael Gibney • Nov. 21, 2024 -
Chip Somodevilla via Getty Images
What might a Trump administration mean for the Biosecure Act?
It’s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners — it’s just a matter of when.
By Amy Baxter • Nov. 20, 2024
Previous
